Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Fig. 5

KPT-251 inhibits prostate tumor growth in vivo. Once tumors were established (80–100 mm3 in size), mice were divided into four different groups (10 mice/group) and treated with varying doses of KPT-251 (10, 30, 100 mg/kg Mondays, Wednesdays and Fridays PO). Tumor volumes were calculated as indicated in MM and followed for 35 days. Group means were calculated and are shown with error bars representing SD for each group. a Tumor weight of PC3 xenografts treated or not with KPT-251. b Time to Progression (TTP) defined as the time (days) necessary to double the tumor volume for each tumor, with Kaplan Meyer curves and calculated in DU145 xenografts. c Hazard ratio values. d Determination of tumor weight in DU145 xenografts treated or not with KPT-251. e Time to Progression (TTP) f Hazard ratio values. g Determination of tumor weight in 22rv1 xenografts treated or not with KPT251. h Time to Progression (TTP) calculated in 22rv1 xenografts. i Hazard ratio values

Back to article page
\